UBS Downgrades CymaBay Therapeutic (CBAY) to Neutral
Tweet
Share
E-mailGet Alerts CBAY Hot Sheet
Price: $32.48 --0%
Rating Summary:
7 Buy, 11 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 12 | New: 26
Rating Summary:
7 Buy, 11 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 12 | New: 26
Join SI Premium – FREE
UBS analyst Eliana Merle downgraded CymaBay Therapeutic (NASDAQ: CBAY) from Buy to Neutral with a price target of $32.50 (from $25.00).
For an analyst ratings summary and ratings history on CymaBay Therapeutic click here. For more ratings news on CymaBay Therapeutic click here.
Shares of CymaBay Therapeutic closed at $32.12 yesterday.
You May Also Be Interested In
- Gartner (IT) PT Lowered to $206 at BMO Capital, adjusting estimates
- Duos Technologies Group (DUOT) PT Raised to $27 at Cantor Fitzgerald on 'Extremely Attractive' Risk/Reward
- Williams Companies (WMB) PT Raised to $103 at Morgan Stanley
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
